No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19

Annals of the Rheumatic Diseases

Volumn 59, Issue 1, 2000, Pages 64-66

  Bengtsson, Anders ^a   Widell, Anders ^a   Elmståhl, Sölve ^a   Sturfelt, Gunnar ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ERYTHEMA INFECTIOSUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARVOVIRUS; PRIORITY JOURNAL; SEROPREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; SENSITIVITY AND SPECIFICITY;

EID: 0034123035     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.1.64     Document Type: Article

References (15)

1. 1 James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26.
2. 2 Herrmann M, Hagenhofer M, Kalden JR. Retroviruses and systemic lupus erythematosus. Imm Review 1996;152: 145-56.
3. 3 Rider JR, Ollier WE, Lock RJ, Brookes ST, Pamphilon DH. Human cytomegalovirus infection and systemic lupus crythematosus. Clin Exp Rheumatol 1997;15:405-9.
4. 4 Török TJ. Parvovirus B19 and human disease. Adv Intern Med 1992;37:431-55.
5. 5 Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988;25:151-3.
6. 6 Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentralbl Bakteriol 1996;284:232-40.
7. 7 Skjoldebrand-Sparre L, Fridell E, Nyman M, Wahren B. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet Gynecol Scand 1996;75:336-9.
8. 8 Nesher G, Osborn TG, Moore TL. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 1995;24:297-303.
9. 9 Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997;40: 103-8.
10. 10 Soloninka CA, Anderson MJ, Laskin CA. Anti-DNA and antilymphocyte antibodies during acute infection with human parvovirus B19. J Rheumatol 1989;16:777-81.
11. 11 Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-50.
12. 12 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. 13 Hansen KE, Arnason J, Bridges AJ. Autoantibodies and common viral illnesses. Semin Arthritis Rheum 1998;27: 263-71.
14. 14 Sturfelt G, Nived O, Norberg R, Thorstensson R, Krook K. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1987;30:382-8.
15. 15 Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum 1983;26:52-62.